Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Poised to Create Standards for Cancer Treatment in the Elderly
May 1, 2017
- 2017 Economic and Fiscal Policy Guidelines Likely to Be Tinged with MOF Color
April 28, 2017
- MHLW to Draw Up Guidelines on Use of MID-NET in Summer
April 28, 2017
- LDP Health Panel Holds Drug Pricing Hearing with Doctor, Pharmacist Groups
April 28, 2017
- Ad-Hoc Generic Prices for “Off-Year” Revisions Acceptable: Chuikyo Bill Payer Reps
April 27, 2017
- JMA’s Nakagawa Says MHLW Should Fuel Generic Industry Realignment: Chuikyo
April 27, 2017
- Savings from Generic Use Increase Sharply from FY2013 through FY2015: MHLW Estimate
April 27, 2017
- New LDP Lawmaker Group on Generics to Draw Up Proposal for 2017 Fiscal Blueprint
April 26, 2017
- Non-Partisan Lawmaker Group on Cooperation with WHO Set Up, Eyeing Asia Pacific Region Congress in Japan this Summer
April 26, 2017
- Me-Too Drugs in Jeopardy? CEFP Working Group Pushes Rigid Drug Selection for Innovation Premium
April 26, 2017
- LDP Health Panel to Compile Resolution on Drug Pricing
April 25, 2017
- Drug Pricing Is Internal Affairs Not Subject to Bilateral Talks: Minister
April 25, 2017
- Apply GDP to Cash-and-Carry Dealers Too: MHLW Panel Members
April 24, 2017
- MHLW Committee Backs Approval of Mundipharma’s PTCL Med Pralatrexate
April 24, 2017
- Commerce Secretary Ross Made No Specific Demand on Drug Pricing: Shiozaki
April 24, 2017
- Negative Opinions Exist for Use of Cost Effective Assessments in Drug Listing: MHLW Official
April 24, 2017
- Sakigake Fast-Track Designation Given to Aducanumab, 4 Other Products
April 24, 2017
- MHLW Panel OKs 2-Year Extension of Reexamination Period for E Keppra due to Development of Dosage for Children Younger than 4
April 24, 2017
- MHLW to Examine Bayer Issue from Pharmaceutical Law Viewpoint without Prejudgment: Bureau Chief
April 21, 2017
- Lawmakers Whispering Thresholds for Off-Year-Revision Products; Top 30% in Discrepancy Rates Floated
April 21, 2017
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…